461 related articles for article (PubMed ID: 15223851)
1. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
[TBL] [Abstract][Full Text] [Related]
2. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
[TBL] [Abstract][Full Text] [Related]
3. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease.
Thadani U; Smith W; Nash S; Bittar N; Glasser S; Narayan P; Stein RA; Larkin S; Mazzu A; Tota R; Pomerantz K; Sundaresan P
J Am Coll Cardiol; 2002 Dec; 40(11):2006-12. PubMed ID: 12475462
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
Firoozi F; Longhurst PA; White MD
BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
[TBL] [Abstract][Full Text] [Related]
5. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
Gresser U; Gleiter CH
Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
[TBL] [Abstract][Full Text] [Related]
6. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
Montorsi F; Corbin J; Phillips S
J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
[TBL] [Abstract][Full Text] [Related]
7. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Mason RG
J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
[No Abstract] [Full Text] [Related]
8. Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.
Perimenis P
Expert Opin Pharmacother; 2005 Jan; 6(1):1-2. PubMed ID: 15709877
[No Abstract] [Full Text] [Related]
9. Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification.
Donatucci C; Eardley I; Buvat J; Gittelman M; Kell P; Segerson T; Homering M; Montorsi F;
J Sex Med; 2004 Nov; 1(3):301-9. PubMed ID: 16422960
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
Kuthe A
Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase-5 inhibitors and their hemodynamic effects.
Prisant LM
Curr Hypertens Rep; 2006 Aug; 8(4):345-51. PubMed ID: 16884667
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
McCullough A
Curr Urol Rep; 2004 Dec; 5(6):451-9. PubMed ID: 15541215
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
Kloner RA
Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
[No Abstract] [Full Text] [Related]
14. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
15. Vardenafil: a new approach to the treatment of erectile dysfunction.
Hellstrom WJ
Curr Urol Rep; 2003 Dec; 4(6):479-87. PubMed ID: 14622502
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
Agarwal P; Sander GE; Giles TD
Am J Geriatr Cardiol; 2004; 13(6):332-5. PubMed ID: 15538074
[No Abstract] [Full Text] [Related]
17. [How effective are PDE-5 inhibitors?].
Jünemann KP
Urologe A; 2003 Apr; 42(4):553-8. PubMed ID: 12715127
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
[TBL] [Abstract][Full Text] [Related]
19. Vardenafil: a review of its use in erectile dysfunction.
Keating GM; Scott LJ
Drugs; 2003; 63(23):2673-703. PubMed ID: 14636086
[TBL] [Abstract][Full Text] [Related]
20. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
Katsarov M
Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
[No Abstract] [Full Text] [Related]
[Next] [New Search]
